Full-Time

Vice President

Multiple Teams

Posted on 11/23/2025

Halozyme

Halozyme

501-1,000 employees

Licenses ENHANZE enzyme for injectable delivery

Compensation Overview

$264k - $387k/yr

+ Bonuses + Sales Incentives + Equity Awards

Lawrence Township, NJ, USA

In Person

Category
Finance & Banking (1)
Required Skills
Product Management
Requirements
  • Bachelor’s degree with minimum of 20 years of experience leading Managed Markets, Patient Support Services, and Trade Relations within the pharmaceutical industry (An equivalent combination of experience and education may be considered)
  • Strong working relationships with Managed Care Organizations, Pharmacy Benefit Managers and other customer channels
  • Product marketing launch experience with emphasis on managed markets, access, and reimbursement
  • Extensive experience working with specialty pharmacies
  • Experience in the Urology, Endocrinology and Primary Care marketplace either in account management, product management or direct selling roles is preferred
  • Strong leadership experience leading Managed Care Account Managers and cross-functional teams
  • Experience managing cross-functional teams and third-party contract organizations
  • Deep financial savvy
  • MBA preferred
Responsibilities
  • Lead team of market access and trade relations professionals and necessary/required consultants across core functions of Market Access, Payers, Patient Support Services, Pricing, Trade Relations and Corporate Accounts.
  • Act as the lead for all Managed Market strategic and tactical plan development and execution to achieve target results; developing a comprehensive annual business plan to support the portfolio
  • Discover opportunities and develop / refine strategies for managed markets customers, physicians, and patient initiatives to drive unencumbered access and favorable reimbursement
  • Develop recommendations to optimize the company’s product formulary positioning and increase product market share via leadership of collaborative pull-through initiatives with field sales and brand marketing
  • Serve as a subject matter expert nsupporting internal and external business partners on pricing recommendations, contract strategies, G2N analyses, and business development deals. Perform ad hoc modeling and, in partnership with marketing and finance, conduct budgetary impact analysis.
  • Collaborate with Finance team to assure 100% accuracy in Government Price Reporting
  • Partner with and advise Chief Commercial Officer to facilitate decision making and implement and evolve key product strategies and messages
  • Act as the lead for Pricing Committee, recommending pricing policy and contracting guidelines
  • Build, lead and propose a detailed department budget supporting portfolio and corporate objectives.
  • Develop and/or coordinate channel tools, resources, and communication materials to support the strategy. Develop innovative programs for collaborators, improving patient access across all channels.
  • Develop reporting procedures for determining effectiveness and ROI when appropriate, of channel marketing investment and communicate results through presentations to Chief Commercial Officer
  • Serve as company lead to develop, strong customer relationships with specialty pharmacies.
  • Interpret and implement legislative changes and internal contracting/strategy changes to MDRP and Federal Government Price Reporting and contracts.
  • Support clinical development and business development activities with strategic insights and guidance pertaining to pricing, reimbursement, payer landscape and other necessary market access parameters.
  • Ensure development, negotiation, and implementation of strategic contracts with all identified Corporate Accounts.
  • Manage state licensing requirements and monitor trends and associated impact to Halozyme operations.
  • Advance relationships with wholesalers, GPOs, IDN’s, 3PLs, retail and specialty pharmacies with emphasis on collaboration, value-add, and compliance.

Halozyme focuses on developing and commercializing ENHANZE, a recombinant hyaluronidase enzyme that temporarily breaks down hyaluronan in subcutaneous tissue to facilitate the delivery of injectable drugs. Through licensing its ENHANZE technology to large pharmaceutical companies, Halozyme enables partners to administer higher-volume or less painful subcutaneous injections. The company earns revenue from upfront licensing fees, milestone payments, and royalties on sales of drugs that use ENHANZE. What sets Halozyme apart is its B2B model centered on a proven collaboration strategy with major pharma players like Roche and Janssen, a track record of FDA-approved fixed-dose subcutaneous combinations, and a focused, royalty-based revenue stream tied to partner products. Halozyme’s goal is to expand access to subcutaneous drug delivery by partnering with more pharmaceutical companies and increasing the number of ENHANZE-enabled therapies registered and sold.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Royalty revenue surged 43% to $241M in Q1 2026 from ENHANZE adoption.
  • New 2026 deals with Vertex, Oruka, GSK expand into ADCs and neuromuscular.
  • $1B share buyback signals strong cash flow exceeding $1.7B 2026 guidance.

What critics are saying

  • GSK ENHANZE ADC trials fail Phase III by 2028 due to immunogenicity.
  • Roche terminates partnership by 2029 after in-house subcutaneous development.
  • $1B buyback depletes reserves as royalties slow post-2027 label expansions.

What makes Halozyme unique

  • ENHANZE enables subcutaneous delivery of high-volume injectables using rHuPH20 enzyme.
  • Hypercon microparticle technology hyperconcentrates drugs for at-home administration.
  • Partners with Roche, Janssen, Pfizer across 10 products in 100+ markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Employee Stock Purchase Program

401(k) Company Match

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-5%
National Today
Apr 13th, 2026
Paragon Capital takes $1.27M stake in Halozyme Therapeutics

Paragon Capital Management has purchased 18,920 shares in Halozyme Therapeutics, valued at approximately $1.27 million, during the fourth quarter of 2025, according to a recent SEC filing. The investment represents a new stake in the San Diego-based biopharmaceutical company. Halozyme specialises in drug delivery technologies, including its ENHANZE platform. Several other institutional investors, including Empowered Funds, Acadian Asset Management, HSBC Holdings and EverSource Wealth Advisors, have also recently adjusted their positions in the company. The investment signals institutional confidence in Halozyme's growth prospects and drug delivery innovations within the pharmaceutical sector.

Yahoo Finance
Apr 9th, 2026
SentinelOne and Halozyme gain traction while Vishay faces margin pressures

SentinelOne, an AI-powered cybersecurity platform provider, is trading at $13.44 per share with a market capitalisation of $4.59 billion. The company's platform autonomously prevents, detects and responds to threats across endpoints, cloud workloads and identity systems. SentinelOne demonstrates strong fundamentals with annual recurring revenue trends showing steady long-term contract flow. The company projects 20% revenue growth over the next 12 months, maintaining momentum from the previous two years. Its gross margin of 74.1% provides financial flexibility for marketing investments and product development. The stock trades at 3.7x forward price-to-sales. Meanwhile, Vishay Intertechnology faces headwinds with declining sales and margin pressures. Halozyme Therapeutics develops technology enabling subcutaneous drug delivery.

Yahoo Finance
Apr 8th, 2026
Halozyme's drug delivery tech outshines struggling beauty brand Olaplex and home products maker Resideo

Halozyme Therapeutics, a small-cap biotech company known for its ENHANZE technology that transforms hours-long intravenous infusions into minutes-long subcutaneous injections, has been identified as a stock worth watching for long-term investors. The company has a market capitalisation of $7.53 billion. In contrast, two small-cap stocks appear less promising. Olaplex, the TikTok-famous hair care brand, has seen revenue decline 15.6% annually over the past three years, with earnings per share falling faster than revenue. The company trades at 23.1x forward P/E. Resideo Technologies, a manufacturer of home comfort and security products, has demonstrated flat earnings per share over five years despite revenue growth, with declining free cash flow margins and eroding returns on capital.

Pharmaceutical Tech
Apr 8th, 2026
Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology.

Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology. 8 April 2026 Halozyme Therapeutics, Inc. today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated ("Vertex"). Under the collaboration, Vertex has licensed Halozyme's Hypercon(TM) technology for use in up to three drug targets. Hypercon(TM) is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. "This collaboration with Vertex underscores the versatility and potential of our Hypercon technology to enable small volume, patient-delivered next-generation biologics," said Helen Torley, President and Chief Executive Officer of Halozyme. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." "We are pleased to add Halozyme's Hypercon drug delivery technology to our toolbox as we pursue transformative therapies for patients with serious diseases," said Mark Bunnage, D.Phil., Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals. "We look forward to exploring the full potential of this technology across our programs of interest." Under the terms of the exclusive agreement, Vertex will make a $15 million upfront payment to Halozyme and potential future milestone payments. Halozyme will also be entitled to royalties on net sales of products developed using the Hypercon(TM) technology. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE(R) drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE(R) has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon(TM) and Surf Bio's hyperconcentration technology. Hypercon(TM) is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon(TM) and Surf Bio's technology complement ENHANZE(R) by enabling creation and delivery of highly concentrated biologics. The Hypercon(TM) technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals. Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex(R) and XYOSTED(R), partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility. Forward-Looking Statements In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, potential new partnerships and innovations, the possible benefits and attributes of the Hypercon(TM) technology, including the potential to reduce injection volume for the same dosage of drugs and biologics and possibly enabling administration in at-home and healthcare-provider settings and statements concerning certain other potential benefits of the Hypercon(TM) technology including facilitating administration of injectable medications through subcutaneous delivery by enabling creation and delivery of highly concentrated biologics and potentially lowering the treatment burden, easing treatment access and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Hypercon's collaboration partner (including the potential regulatory approval and launch of such products as a result of such efforts and the potential future market opportunity for such products) and Hypercon's potential receipt of upfront payments and payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue" and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether payments due to Hypercon under the collaboration agreement will be received and whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Sydney Charlton Teneo 917-972-8407 [email protected]

The Pharma Letter
Apr 8th, 2026
Halozyme inks license agreement with Vertex.

Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026

INACTIVE